


Amendment to the Claims

The listing of claims replaces all prior versions, and listings, of claims in the application:

1. (Currently Amended) In a conjugate comprising a taxoid and an omega-3 fatty acid, the improvement wherein the taxoid is a second-generation taxoid having the following structure:



wherein R¹ represents C1-C6 alkyl or alkenyl, dialkylamino or alkylamino, or alkoxy;


R² represents C3-C5 alkyl or alkenyl or trifluoromethyl;

R³ represents H, methyl, methoxy, chloro, fluoro or azido;

R⁴ represents C3-C6 cycloalkyl or cycloalkenyl or an alkoxy;


R⁵ and R⁶ are both hydrogens or R⁵ and R⁶ together represent oxycarbonyl, forming thereby a cyclic carbonate.

2. (Currently Amended) A conjugate according to claim 1, wherein the second-generation taxoid is SB-T-1214 having the following structure:




wherein R¹ is cyclopropyl, R² is 2-methyl-1-propenyl, and R³ is H.

3. (Currently Amended) A conjugate according to claim 1, wherein the second-generation taxoid is SB-T-1213 having the following structure:




wherein: R¹ is C₃H₅, R² is 2-methyl-1-propenyl, and R³ is H.

4. (Currently Amended) A conjugate according to claim 1, wherein the second-generation taxoid is SB-T-1216 having the following structure:



wherein: R¹ is (CH₃)₂N, R² is 2-methyl-1-propenyl, and R³ is H.


5. (Currently Amended) A conjugate according to claim 1, wherein the second-generation taxoid is SB-T-1103 having the following structure:



wherein: R¹ is C₂H₅, R² is 2-methylpropyl, and R³ is H.


6. (Original) A conjugate according to claim 1, wherein the second-generation taxoid is ortataxel.

7. (Currently Amended) A conjugated conjugate according to claim 1, wherein the second-generation taxoid is SB-T-11033 having the following structure:




wherein: R¹ is C₂H₅, R² is 2-methylpropyl, and R³ is CH₃O.

8. (Currently Amended) A conjugated conjugate according to claim 1, wherein the second-generation taxoid is SB-T-1104 having the following structure:




wherein: R¹ is cyclopropyl, R² is 2-methylpropyl, and R³ is H.

9. (Currently Amended) A conjugated conjugate according to claim 1, wherein the second-generation taxoid is SB-T-11043 having the following structure:




wherein: R¹ is cyclopropyl, R² is 2-methylpropyl, and R³ is CH₃O.

10. (Currently Amended) A conjugated conjugate according to claim 1, wherein the second-generation taxoid is SB-T-1107 having the following structure:




wherein: R¹ is CH₃O, R² is 2-methylpropyl, and R³ is H.

11. (Currently Amended) A conjugated conjugate according to claim 1, wherein the second-generation taxoid is SB-T-11073 having the following structure:




wherein: R¹ is CH₃O, R² is 2-methylpropyl, and R³ is CH₃O.

12. (Currently Amended) A conjugated conjugate according to claim 1, wherein the second-generation taxoid is SB-T-121303 having the following structure:




wherein: R¹ is C₂H₅, R² is 2-methyl-1-propenyl, and R³ is CH₃O.

13. (Currently Amended) A conjugated conjugate according to claim 1, wherein the second-generation taxoid is SB-T-121403 having the following structure:




wherein: R¹ is cyclopropyl, R² is 2-methyl-1-propenyl, and R³ is CH₃O.

14. (Currently Amended) A conjugated conjugate according to claim 1, wherein the second-generation taxoid is SB-T-121603 having the following structure:




wherein: R¹ is (CH₃)₂N, R² is 2-methyl-1-propenyl, and R³ is CH₃O.

15. (Currently Amended) A conjugated conjugate according to claim 1, wherein the second-generation taxoid is SB-T-121703 having the following structure:




wherein: R¹ is CH₃O, R² is 2-methyl-1-propenyl, and R³ is CH₃O.

16. (Currently Amended) A conjugated conjugate according to claim 1, wherein the second-generation taxoid is SB-T-12821 having the following structure:



wherein: R¹ is (CH₃)₂N, R² is trifluoromethyl, and R³ is H.

17. (Currently Amended) A conjugated conjugate according to claim 1, wherein the second-generation taxoid is SB-T-128221-3 having the following structure:




wherein: R¹ is C₂H₅, R² is trifluoromethyl, and R³ is CH₂O.

18. (Original) A conjugate according to claim 1, wherein the omega-3 fatty acid is docosahexanoic acid.

19. (Original) A conjugate according to claim 1, wherein the omega-3 fatty acid is eicosapentaenoic acid.

20. (Original) A conjugate according to claim 1, wherein the omega-3 fatty acid is α -linolenic acid.

21. (Currently Amended) In a pharmaceutical composition comprising a conjugate comprising a taxoid and an omega 3-fatty acid, the improvement wherein the taxoid is a second-generation taxoid having the following structure:



wherein R¹ represents C1-C6 alkyl or alkenyl, dialkylamino or alkylamino, or alkoxy;

R² represents C3-C5 alkyl or alkenyl or trifluoromethyl;


R³ represents H, methyl, methoxy, chloro, fluoro or azido;

R⁴ represents C3-C6 cycloalkyl or cycloalkenyl or an alkoxy;

R⁵ and R⁶ are both hydrogens or R⁵ and R⁶ together represent oxycarbonyl, forming thereby a cyclic carbonate.


22. (Original) A pharmaceutical composition according to claim 21, wherein the second-generation taxoid is ortataxel.

23. (Currently Amended) A pharmaceutical composition according to claim 21, wherein the second-generation taxoid is SB-T-121303 having the following structure:




wherein: R¹ is C₂H₅, R² is 2-methyl-1-propenyl, and R³ is CH₃O

24. (Currently Amended) A pharmaceutical composition according to claim 21, wherein the second-generation taxoid is SB-T-1103 having the following structure:




wherein: R¹ is C₂H₅, R² is 2-methylpropyl, and R³ is H.

25. (Currently Amended) A pharmaceutical composition according to claim 21, wherein the second-generation taxoid is SB-T-1214 having the following structure:




wherein R¹ is cyclopropyl, R² is 2-methyl-1-propenyl, and R³ is H.

26. (Currently Amended) A pharmaceutical composition according to claim 21, wherein the second-generation taxoid is SB-T-1216 having the following structure:




wherein: R¹ is (CH₃)₂N, R² is 2-methyl-1-propenyl, and R³ is H.

27. (Currently Amended) A pharmaceutical composition according to claim 21, wherein the second-generation taxoid is SB-T-1103 having the following structure:




wherein: R¹ is C₂H₅, R² is 2-methylpropyl, and R³ is CH₃O.

28. (Currently Amended) A pharmaceutical composition according to claim 21, wherein the second-generation taxoid is SB-T-1104 having the following structure:




wherein: R¹ is cyclopropyl, R² is 2-methylpropyl, and R³ is H.

29. (Currently Amended) A pharmaceutical composition according to claim 21, wherein the second-generation taxoid is SB-T-11043 having the following structure:




wherein: R¹ is cyclopropyl, R² is 2-methylpropyl, and R³ is CH₃O.

30. (Currently Amended) A pharmaceutical composition according to claim 21, wherein the second-generation taxoid is SB-T-1107 having the following structure:




wherein: R¹ is CH₃O, R² is 2-methylpropyl, and R³ is H.

31. (Currently Amended) A pharmaceutical composition according to claim 21, wherein the second-generation taxoid is SB-T-11073 having the following structure:




wherein: R¹ is CH₃O, R² is 2-methylpropyl, and R³ is CH₃O.

32. (Currently Amended) A pharmaceutical composition according to claim 21, wherein the second-generation taxoid is SB-T-1213 having the following structure:




wherein: R¹ is C₂H₅, R² is 2-methyl-1-propenyl, and R³ is H.

33. (Currently Amended) A pharmaceutical composition according to claim 21, wherein the second-generation taxoid is SB-T-121403 having the following structure:




wherein: R¹ is cyclopropyl, R² is 2-methyl-1-propenyl, and R³ is CH₃O.

34. (Currently Amended) A pharmaceutical composition according to claim 21, wherein the second-generation taxoid is SB-T-121603 having the following structure:




wherein: R¹ is (CH₃)₂N, R² is 2-methyl-1-propenyl, and R³ is CH₃O.

35. (Currently Amended) A pharmaceutical composition according to claim 21, wherein the second-generation taxoid is SB-T-121703 having the following structure:




wherein: R¹ is CH₃O, R² is 2-methyl-1-propenyl, and R³ is CH₃O.

36. (Currently Amended) A pharmaceutical composition according to claim 21, wherein the second-generation taxoid is SB-T-12821 having the following structure:



wherein: R¹ is (CH₃)₂N, R² is trifluoromethyl, and R³ is H.

37. (Currently Amended) A pharmaceutical composition according to claim 21, wherein the second-generation taxoid is SB-T-128221-3 having the following structure:




wherein: R¹ is C₂H₅, R² is trifluoromethyl, and R³ is CH₃O.

38. (Original) A pharmaceutical composition according to claim 21, wherein the omega-3 fatty acid is docosahexanoic acid.

39. (Original) A pharmaceutical composition according to claim 21, wherein the omega-3 fatty acid is eicosapentaenoic acid.

40. (Original) A pharmaceutical composition according to claim 21, wherein the omega-3 fatty acid is α -linolenic acid.

41. (Currently Amended) In a method for treating cancer in a human in need thereof, the method comprising administering an effective amount of a conjugate comprising a taxoid and an omega 3-fatty acid, the improvement wherein the taxoid is a second-generation taxoid having the following structure:



wherein R^1 represents C1-C6 alkyl or alkenyl, dialkylamino or alkylamino, or alkoxy;

R^2 represents C3-C5 alkyl or alkenyl or trifluoromethyl;


R^3 represents H, methyl, methoxy, chloro, fluoro or azido;

R^4 represents C3-C6 cycloalkyl or cycloalkenyl or an alkoxy;

R^5 and R^6 are both hydrogens or R^5 and R^6 together represent oxycarbonyl, forming thereby a cyclic carbonate.


42. (Original) A method according to claim 41, wherein the second-generation taxoid is ortataxel.

43. (Currently Amended) A method according to claim 41, wherein the second-generation taxoid is SB-T-121303 having the following structure:




wherein: R¹ is C₂H₅, R² is 2-methyl-1-propenyl, and R³ is CH₃O.

44. (Currently Amended) A method according to claim 41, wherein the second-generation taxoid is SB-T-1103 having the following structure:




wherein: R¹ is C₂H₅, R² is 2-methylpropyl, and R³ is H.

45. (Currently Amended) A method according to claim 41, wherein the second-generation taxoid is SB-T-1214 having the following structure:




wherein R¹ is cyclopropyl, R² is 2-methyl-1-propenyl, and R³ is H.

46. (Currently Amended) A method according to claim 41, wherein the second-generation taxoid is SB-T-1216 having the following structure:




wherein: R¹ is (CH₃)₂N, R² is 2-methyl-1-propenyl, and R³ is H.

47. (Currently Amended) A method according to claim 41, wherein the second-generation taxoid is SB-T-11033 having the following structure:




wherein: R¹ is C₂H₅, R² is 2-methylpropyl, and R³ is CH₃O.

48. (Currently Amended) A method according to claim 41, wherein the second-generation taxoid is SB-T-1104 having the following structure:




wherein: R¹ is cyclopropyl, R² is 2-methylpropyl, and R³ is H.

49. (Currently Amended) A method according to claim 41, wherein the second-generation taxoid is SB-T-11043 having the following structure:




wherein: R¹ is cyclopropyl, R² is 2-methylpropyl, and R³ is CH₃O.

50. (Currently Amended) A method according to claim 41, wherein the second-generation taxoid is SB-T-1107 having the following structure:




wherein: R¹ is CH₃O, R² is 2-methylpropyl, and R³ is H.

51. (Currently Amended) A method according to claim 41, wherein the second-generation taxoid is SB-T-11073 having the following structure:




wherein: R¹ is CH₃O, R² is 2-methylpropyl, and R³ is CH₃O.

52. (Currently Amended) A method according to claim 41, wherein the second-generation taxoid is SB-T-1213 having the following structure:




wherein: R¹ is C₂H₅, R² is 2-methyl-1-propenyl, and R³ is H.

53. (Currently Amended) A method according to claim 41, wherein the second-generation taxoid is SB-T-121403 having the following structure:




wherein: R¹ is cyclopropyl, R² is 2-methyl-1-propenyl, and R³ is CH₃O.

54. (Currently Amended) A method according to claim 41, wherein the second-generation taxoid is SB-T-121603 having the following structure:




wherein: R¹ is (CH₃)₂N, R² is 2-methyl-1-propenyl, and R³ is CH₃O.

55. (Currently Amended) A method according to claim 41, wherein the second-generation taxoid is SB-T-121703 having the following structure:




wherein: R¹ is CH₃O, R² is 2-methyl-1-propenyl, and R³ is CH₃O.

56. (Currently Amended) A method according to claim 41, wherein the second-generation taxoid is SB-T-12821 having the following structure:



wherein: R¹ is (CH₃)₂N, R² is trifluoromethyl, and R³ is H.

57. (Currently Amended) A method according to claim 41, wherein the second-generation taxoid is SB-T-128221-3 having the following structure:



wherein: R¹ is C₂H₅, R² is trifluoromethyl, and R³ is CH₃O.

58. (Original) A method according to claim 41, wherein the omega-3 fatty acid is docosahexanoic acid.

59. (Original) A method according to claim 41, wherein the omega-3 fatty acid is eicosapentaenoic acid.

60. (Original) A method according to claim 41, wherein the omega-3 fatty acid is α -linolenic acid.

61. (Original) A method according to claim 41, wherein the cancer is breast cancer.

62. (Original) A method according to claim 41, wherein the cancer is ovarian cancer.

63. (Original) A method according to claim 41, wherein the cancer is lung cancer.

64. (Original) A method according to claim 41, wherein the cancer is head cancer.

65. (Original) A method according to claim 41, wherein the cancer is neck cancer.

66. (Original) A method according to claim 41, wherein the cancer is colon cancer.
67. (Original) A method according to claim 41, wherein the cancer is pancreatic cancer.
68. (Original) A method according to claim 41, wherein the cancer is melanoma cancer.
69. (Original) A method according to claim 41, wherein the cancer is brain cancer.
70. (Original) A method according to claim 41, wherein the cancer is renal cancer.
71. (Original) A method according to claim 41, wherein the cancer is prostate cancer.